Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for tough lung cancer: targeted drug cocktails enter human testing

NCT ID NCT07286149

Recruiting now Disease control Sponsor: Merck Sharp & Dohme LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 5 times

Summary

This study tests a new targeted therapy called MK-1084, alone or combined with other drugs, in 190 people with advanced non-squamous non-small cell lung cancer that has a specific KRAS G12C mutation and has worsened after prior treatments. The main goals are to check safety and see if tumors shrink. It is an early-phase trial, so results are not yet known.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
MK-1084 (targeted therapy) combined with patritumab deruxtecan, sacituzumab tirumotecan, or cetuximab
What this could lead to
If successful, this could lead to new combination treatment options for people with a specific type of advanced lung cancer that has stopped responding to prior therapies.
What could go wrong
This is an early-phase trial (Phase 1b/2) with a small number of participants, so the treatments may not prove effective or safe enough for wider use. Side effects from the drug combinations could be significant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC NONSQUAMOUS NON-SMALL CELL LUNG CANCER WITH KRAS G12C MUTATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung adenocarcinoma lung cancer lung neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG NEOPLASM MALIGNANT

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Alexandra General Hospital of Athens-ONCOLOGY DEPT. ( Site 0205)

    RECRUITING

    Athens, Attica, 115 28, Greece

  • Bradfordhill ( Site 0160)

    RECRUITING

    Santiago, Region M. de Santiago, 8420383, Chile

  • Centro de Estudios Clínicos SAGA-CECSAGA ( Site 0162)

    RECRUITING

    Santiago, Region M. de Santiago, 7500653, Chile

  • Clermont Oncology Center ( Site 0041)

    RECRUITING

    Clermont, Florida, 34711, United States

  • FALP ( Site 0161)

    RECRUITING

    Santiago, Region M. de Santiago, 7500921, Chile

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto ( Site 0286)

    RECRUITING

    São José do Rio Preto, São Paulo, 15090-000, Brazil

  • Fundação Pio XII - Hospital de Câncer de Barretos ( Site 0282)

    RECRUITING

    Barretos, São Paulo, 14784-400, Brazil

  • Guangdong Provincial People s Hospital ( Site 0300)

    RECRUITING

    Guangzhou, Guangdong, 510120, China

  • Hong Kong United Oncology Centre ( Site 0232)

    RECRUITING

    Jordan, 000000, Hong Kong

  • Hospital Clinic de Barcelona ( Site 0092)

    RECRUITING

    Barcelona, 08036, Spain

  • Hospital Paulistano ( Site 0280)

    RECRUITING

    São Paulo, São Paulo, 01321001, Brazil

  • Hospital São Lucas da PUCRS ( Site 0283)

    RECRUITING

    Porto Alegre, Rio Grande do Sul, 90610-000, Brazil

  • Hospital Universitario Virgen Macarena ( Site 0093)

    RECRUITING

    Seville, 41009, Spain

  • IRCCS - Istituto Romagnolo per lo Studio dei Tumori (IRST) "Dino Amadori" ( Site 0176)

    RECRUITING

    Meldola, Forli-Cesena, 47014, Italy

  • Institut Català d'Oncologia - L'Hospitalet ( Site 0090)

    RECRUITING

    Hospitalet, Barcelona, 08908, Spain

  • Meir Medical Center ( Site 0181)

    RECRUITING

    Kfar Saba, 4428164, Israel

  • Papageorgiou General Hospital of Thessaloniki ( Site 0206)

    RECRUITING

    N.Efkarpia, Thessaloniki, 564 29, Greece

  • Prince of Wales Hospital ( Site 0231)

    RECRUITING

    Shatin, Hong Kong

  • Providence Oncology and Hematology Care Clinic - Westside ( Site 0059)

    RECRUITING

    Portland, Oregon, 97225, United States

  • Providence Portland Medical Center ( Site 0043)

    RECRUITING

    Portland, Oregon, 97213, United States

  • Queen Mary Hospital ( Site 0230)

    RECRUITING

    Hong Kong, 000000, Hong Kong

  • Severance Hospital, Yonsei University Health System ( Site 0080)

    RECRUITING

    Seoul, 03722, South Korea

  • Shaare Zedek Medical Center ( Site 0186)

    RECRUITING

    Jerusalem, 9103102, Israel

  • Sheba Medical Center ( Site 0180)

    RECRUITING

    Ramat Gan, 5265601, Israel

  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA" ( Site 0204)

    RECRUITING

    Athens, Attica, 115 27, Greece

  • UniversitaetsklInikum Tuebingen ( Site 0192)

    RECRUITING

    Tübingen, Baden-Wurttemberg, 72076, Germany

  • University of Illinois Hospital & Health Sciences System ( Site 0044)

    RECRUITING

    Chicago, Illinois, 60612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.